Market capitalization | $13.25b |
Enterprise Value | $12.95b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 37.76 |
P/S ratio (TTM) P/S ratio | 38.65 |
P/B ratio (TTM) P/B ratio | 27.41 |
Revenue growth (TTM) Revenue growth | 22.13% |
Revenue (TTM) Revenue | $342.96m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
18 Analysts have issued a Insmed Incorporated forecast:
18 Analysts have issued a Insmed Incorporated forecast:
Sep '24 |
+/-
%
|
||
Revenue | 343 343 |
22%
22%
|
|
Gross Profit | 260 260 |
21%
21%
|
|
EBITDA | -693 -693 |
6%
6%
|
EBIT (Operating Income) EBIT | -704 -704 |
5%
5%
|
Net Profit | -864 -864 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Head office | United States |
CEO | Will Lewis |
Employees | 912 |
Founded | 1988 |
Website | www.insmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.